NZ719185A - Crystalline forms of therapeutic compounds and uses thereof - Google Patents

Crystalline forms of therapeutic compounds and uses thereof

Info

Publication number
NZ719185A
NZ719185A NZ719185A NZ71918514A NZ719185A NZ 719185 A NZ719185 A NZ 719185A NZ 719185 A NZ719185 A NZ 719185A NZ 71918514 A NZ71918514 A NZ 71918514A NZ 719185 A NZ719185 A NZ 719185A
Authority
NZ
New Zealand
Prior art keywords
crystalline forms
pharmaceutical compositions
particles
therapeutic compounds
yloxy
Prior art date
Application number
NZ719185A
Other languages
English (en)
Inventor
Elizabeth Enlow
Minh Ngoc Nguyen
Winston Z Ong
Original Assignee
Kala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc
Publication of NZ719185A publication Critical patent/NZ719185A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NZ719185A 2013-11-01 2014-10-31 Crystalline forms of therapeutic compounds and uses thereof NZ719185A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361898741P 2013-11-01 2013-11-01
US201462039192P 2014-08-19 2014-08-19
US201462039177P 2014-08-19 2014-08-19
PCT/US2014/063444 WO2015066482A1 (en) 2013-11-01 2014-10-31 Crystalline forms of therapeutic compounds and uses thereof

Publications (1)

Publication Number Publication Date
NZ719185A true NZ719185A (en) 2017-11-24

Family

ID=53005200

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ719185A NZ719185A (en) 2013-11-01 2014-10-31 Crystalline forms of therapeutic compounds and uses thereof

Country Status (10)

Country Link
US (6) US9458169B2 (enExample)
EP (1) EP3062618B1 (enExample)
JP (2) JP6426194B2 (enExample)
KR (1) KR20160099084A (enExample)
CN (2) CN106061261B (enExample)
AU (1) AU2014342042B2 (enExample)
CA (1) CA2928658A1 (enExample)
MX (1) MX355330B (enExample)
NZ (1) NZ719185A (enExample)
WO (1) WO2015066482A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10864219B2 (en) * 2012-05-03 2020-12-15 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) * 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) * 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2015066482A1 (en) * 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) * 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324716B2 (en) * 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2019002629A (es) * 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
KR20200074179A (ko) * 2017-10-20 2020-06-24 칼라 파마슈티컬스, 인크. Ret9 및 vegfr2 억제제
WO2019118826A1 (en) * 2017-12-15 2019-06-20 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer using exosomes-associated gene editing
AU2019242912B2 (en) 2018-03-28 2025-07-17 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in DNA isolated from exosomes
CN115279769A (zh) 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
JP7620629B2 (ja) * 2019-12-02 2025-01-23 アカデミア シニカ ＰＤＩＡ４阻害剤及びβ細胞発症機序を阻害し、糖尿病を治療するためのこのＰＤＩＡ４阻害剤の使用
US20230057383A1 (en) * 2020-03-21 2023-02-23 Mihan JAFARI JAVID Composition and methods for prevention and treatment of vascular disorders, neurodegenerative disease and neuropathic disorders
KR102491010B1 (ko) * 2021-09-07 2023-01-20 경희대학교 산학협력단 현탁액에서의 물리적 분쇄를 이용한 안정상 결정 제조방법
CN115820545A (zh) * 2022-12-28 2023-03-21 中国农业大学 提高卵母细胞体外成熟率的培养基及其应用
SI4489884T1 (sl) 2023-01-18 2025-12-31 Nanoform Finland Oyj Postopek za kristalizacijo zdravilnih učinkovin
CN119097710B (zh) * 2024-09-11 2025-09-02 山东大学齐鲁医院 Ape1抑制剂在制备治疗过敏性鼻炎药物中的应用

Family Cites Families (337)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
CA1325382C (en) 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5442039A (en) 1989-07-17 1995-08-15 The Dow Chemical Company Mesogenic polycyanates and thermosets thereof
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5190956A (en) 1990-09-07 1993-03-02 Schering Corporation Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
CA2113115A1 (en) 1991-07-29 1993-02-18 Vlad E. Gregor Quinazoline derivatives as acetylcholinesterase inhibitors
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5364884A (en) 1993-01-21 1994-11-15 Baylor College Of Medicine Arginine compounds as ocular hypotensive agents
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
WO1995003356A1 (en) 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
DK0744940T3 (da) 1994-02-17 1999-07-26 Pankaj Modi Medikamenter, vacciner og hormoner i polylactidovertrukne mikrokugler
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
GB9406094D0 (en) 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6106819A (en) 1996-12-31 2000-08-22 Sucher; David F. Methods of treating headache and functional extraocular and intraocular myotendinitis
ZA9711732B (en) 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
CA2276532C (en) 1997-01-06 2008-06-17 Cerus Corporation Frangible compounds for pathogen inactivation
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
FR2772763B1 (fr) 1997-12-24 2004-01-23 Sod Conseils Rech Applic Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6165509A (en) 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
HUP0103520A3 (en) 1998-09-29 2003-01-28 Wyeth Holdings Corp Madison Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them
EP1119567B1 (en) 1998-10-08 2005-05-04 AstraZeneca AB Quinazoline derivatives
US6372246B1 (en) 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
JP2002534363A (ja) 1999-01-08 2002-10-15 エミスフェアー・テクノロジーズ・インク ポリマー性デリバリー剤及びデリバリー剤化合物
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
BRPI0017548B8 (pt) * 1999-02-10 2023-05-02 Astrazeneca Ab Composto
SK12112001A3 (sk) 1999-02-27 2001-12-03 Boehringer Ingelheim Pharma Kg 4-amino-chinazolínové a chinolínové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
WO2001074790A2 (en) 2000-03-30 2001-10-11 The Penn State Research Foundation Novel compounds for enhancing chemotherapy
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CN1315822C (zh) 2000-08-09 2007-05-16 阿斯特拉曾尼卡有限公司 具有vegf抑制活性的喹啉衍生物
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP4361727B2 (ja) 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
FR2814167B1 (fr) 2000-09-15 2002-11-08 Aventis Pharma Sa Preparation de la camptothecine et de ses derives
CA2426684A1 (en) 2000-10-25 2002-08-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2000202A (en) 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB2370839A (en) 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex useful for disease control
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
JP4329003B2 (ja) 2001-03-23 2009-09-09 バイエル コーポレイション Ｒｈｏキナーゼ阻害剤
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
DE10128110A1 (de) 2001-06-11 2003-01-02 Univ Hannover Verbindungen zum Anlagern an Nucleinsäuren
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
EP1408971A4 (en) 2001-06-21 2006-01-25 Ariad Pharma Inc NEW QUINOLINES AND THEIR USES
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
AU2002322289A1 (en) 2001-06-22 2003-01-08 Johns Hopkins University School Of Medicine Biodegradable polymer coompositions
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
WO2003053926A1 (en) 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Novel phenylalanine derivative
AU2002359694A1 (en) 2001-12-14 2003-06-30 Smithkline Beecham Corporation Compounds and methods
CN1625555A (zh) * 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2006220411B2 (en) 2002-03-20 2008-06-26 Alkermes, Inc. Inhalable Sustained Therapeutic Formulations
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
EP1510221A4 (en) 2002-06-03 2009-04-29 Mitsubishi Tanabe Pharma Corp MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
JP4513007B2 (ja) 2002-09-26 2010-07-28 アステラス製薬株式会社 薬物吸収性改善剤
AU2003291362B2 (en) 2002-11-08 2009-01-15 Schering Corporation Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
EP1567506A4 (en) 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
RU2350611C1 (ru) 2002-12-24 2009-03-27 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
KR20050087863A (ko) 2002-12-24 2005-08-31 아스트라제네카 아베 퀴나졸린 화합물
AU2003294142A1 (en) 2002-12-24 2004-07-22 Astrazeneca Ab Therapeutic quinazoline derivatives
JPWO2004060400A1 (ja) 2003-01-06 2006-05-11 那波　宏之 上皮成長因子受容体を分子標的とする抗精神病薬
US20050266090A1 (en) 2003-04-29 2005-12-01 Ales Prokop Nanoparticular targeting and therapy
WO2005044224A2 (en) 2003-05-02 2005-05-19 Case Western Reserve University Drug delivery system based on polymer nanoshells
JP2007501683A (ja) 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050009809A1 (en) 2003-07-11 2005-01-13 Matthias Gerlach Acridine derivatives and their use as medicaments
DE10331500A1 (de) 2003-07-11 2005-02-24 Zentaris Gmbh Neue Acridin-Derivate und deren Verwendung als Arzneimittel
US20050124562A1 (en) 2003-09-23 2005-06-09 Joseph Guiles Bis-quinazoline compounds for the treatment of bacterial infections
WO2005035521A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Substituted quinolines as mcr modulators
TWI347940B (en) 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
JP4932495B2 (ja) 2004-01-23 2012-05-16 アムゲン インコーポレイテッド 化合物及び使用方法
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
SE0400284D0 (sv) 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
WO2005082340A2 (en) 2004-02-20 2005-09-09 Chiron Corporation Modulation of inflammatory and metastatic processes
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
AU2005219413A1 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
MXPA06010849A (es) 2004-03-25 2007-03-08 Bausch & Lomb Uso de loteprednol etabonato para el tratamiento del ojo seco.
WO2005097134A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
US7745436B2 (en) 2004-04-13 2010-06-29 Synta Pharmaceuticals Corporation Disalt inhibitors of IL-12 production
WO2006097793A2 (en) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
MXPA06012663A (es) 2004-05-03 2007-01-16 Novartis Ag Combinaciones que comprenden un agonista del receptor s1p y un inhibidor de quinasa jak3.
US20100226931A1 (en) 2004-06-24 2010-09-09 Nicholas Valiante Compounds for immunopotentiation
AU2005326322B2 (en) 2004-07-01 2009-02-05 Yale University Targeted and high density drug loaded polymeric materials
CN101031551A (zh) 2004-07-06 2007-09-05 安吉永生物制药公司 针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂
EP1797877A4 (en) 2004-09-13 2010-12-15 Eisai Co Ltd JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
CA2580659C (en) 2004-09-15 2013-02-26 Ivx Animal Health, Inc. Corticosteroid having low systemic absorption
KR20070073813A (ko) * 2004-09-27 2007-07-10 아스트라제네카 아베 Ａｚｄ2171 및 이마티닙을 포함하는 암의 병합 요법
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
EP3173072A1 (en) 2004-10-01 2017-05-31 Ramscor, Inc. Conveniently implantable sustained release drug compositions
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
WO2006040526A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives for use against cancer
WO2006044660A2 (en) 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
ES2407979T3 (es) 2004-12-10 2013-06-17 Kala Pharmaceuticals, Inc. Copolímeros de bloques de poli(éter-anhídrido) funcionalizados
KR20070108909A (ko) 2005-02-18 2007-11-13 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 알데스류킨과 함께 사용하는 항혈관형성제
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
DE102005009705A1 (de) 2005-03-03 2006-09-07 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
DE102005011786A1 (de) 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
US8048889B2 (en) 2005-03-29 2011-11-01 Xtl Biopharmaceuticals Ltd. 3,4-disubstituted coumarin and quinolone compounds
SG161217A1 (en) 2005-04-01 2010-05-27 Insa Rouen New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
CA2607608A1 (en) 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
EP1888529A2 (en) 2005-05-18 2008-02-20 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
BRPI0610147A2 (pt) 2005-05-25 2010-06-01 Wyeth Corp método para preparar e sintetizar 3-cianoquinolinas substituìdas e 4-amino-3-cianoquinolinas
CN101180269A (zh) 2005-05-25 2008-05-14 惠氏公司 制备3-氰基-喹啉的方法和由其制得的中间体
CN1313449C (zh) 2005-07-14 2007-05-02 沈阳中海生物技术开发有限公司 新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
WO2007015569A1 (ja) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
FR2889527A1 (fr) 2005-08-05 2007-02-09 Servier Lab Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4792262B2 (ja) 2005-09-09 2011-10-12 富士フイルム株式会社 有機電界発光素子及び錯体化合物
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
US20080267876A1 (en) 2005-09-20 2008-10-30 Yissum Research Development Company Nanoparticles for Targeted Delivery of Active Agent
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN1955183B (zh) 2005-10-28 2011-04-20 中国医学科学院药物研究所 20-位酯化的喜树碱衍生物、其制法和其药物组合物与用途
US20070149523A1 (en) 2005-11-14 2007-06-28 Jan Ehlert Thiazole Analogues and Uses Thereof
EP1785420A1 (en) 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
ATE482690T1 (de) 2005-12-14 2010-10-15 Hoffmann La Roche Hcv-prodrug-formulierung
WO2007076448A2 (en) 2005-12-23 2007-07-05 Alcon, Inc. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
WO2007081978A2 (en) 2006-01-11 2007-07-19 Angion Biomedica Corporation Modulators of hepatocyte growth factor / c-met activity
US20070196860A1 (en) 2006-01-18 2007-08-23 Invitrogen Corporation Methods for Measuring Real Time Kinase Activity
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
EP2010677A4 (en) 2006-02-24 2010-04-14 Investigen Inc METHODS AND COMPOSITIONS FOR DETECTION OF POLYNUCLEOTIDES
GB2444101A (en) 2006-02-24 2008-05-28 Investigen Inc Methods and compositions for detecting polynucleotides
WO2007104696A1 (en) 2006-03-15 2007-09-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antimalarial agents having polyaromatic structure
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
MX2008013212A (es) 2006-04-14 2008-10-22 Astrazeneca Ab 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2007133808A2 (en) 2006-05-15 2007-11-22 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
AU2006343604A1 (en) 2006-05-15 2007-11-22 Xtl Biopharmaceuticals, Ltd. 3,4-disubstituted coumarin and quinolone compounds
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US20110053931A1 (en) 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
EP2044939A1 (en) 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
WO2008006050A2 (en) 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2008030557A2 (en) 2006-09-08 2008-03-13 Johns Hopkins University Compositions and methods for enhancing transport through mucus
EP2061469B8 (en) 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
US8821943B2 (en) 2006-09-12 2014-09-02 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US20080096193A1 (en) 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
CL2007003158A1 (es) 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US7915287B2 (en) 2006-12-20 2011-03-29 Amgen Inc. Substituted heterocycles and methods of use
CN100540551C (zh) 2007-02-01 2009-09-16 中国药科大学 喹啉衍生物、其制备方法及其医药用途
CN100540552C (zh) 2007-02-01 2009-09-16 中国药科大学 3-氰基喹啉衍生物、其制备方法及其医药用途
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
JP2008214323A (ja) 2007-03-08 2008-09-18 Kyowa Hakko Kogyo Co Ltd 皮膚疾患の治療及び／または予防剤
KR20090130051A (ko) 2007-03-14 2009-12-17 엑셀리시스, 인코포레이티드 헤지호그 경로의 억제제
WO2008113161A1 (en) 2007-03-19 2008-09-25 Ulysses Pharmaceutical Products Inc. Phosphate prodrugs of quinazolinyl nitrofurans, methods of obtaining, and use of same
DE102007015169A1 (de) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
DE102007017654A1 (de) 2007-04-12 2008-10-16 Henkel Ag & Co. Kgaa Bis(hydroxychinolin)-Metallkomplexe als Bleichkatalysatoren
CN101317847B (zh) 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
TW200904817A (en) 2007-06-19 2009-02-01 Astrazeneca Ab Compounds and uses thereof
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CA2708319A1 (en) 2007-07-27 2009-02-05 The Board Of Trustees Of The Leland Stanford Junior University Supramolecular functionalization of graphitic nanoparticles for drug delivery
CN101108846B (zh) 2007-08-10 2011-02-09 东南大学 4-芳香氨基喹唑啉衍生物及制备方法和在制药中的应用
US20090062337A1 (en) 2007-08-31 2009-03-05 Wysis Technology Foundation, Inc. Treatment of Microbial Infections
WO2009030224A2 (de) 2007-09-07 2009-03-12 Schebo Biotech Ag Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
DE102008012435A1 (de) * 2008-02-29 2009-09-03 Schebo Biotech Ag Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009042613A1 (en) 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]
US7863283B2 (en) 2008-01-17 2011-01-04 Bayer Schering Pharma Ag Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments
WO2009094211A1 (en) 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Quinazoline compounds and methods of treating cancer
CN102016590A (zh) 2008-02-28 2011-04-13 生命技术公司 荧光偏振hERG试验
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
AU2009246263B2 (en) 2008-05-14 2014-08-21 Amgen Inc. Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer
EP2149565A1 (de) 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
TWI580441B (zh) 2008-09-19 2017-05-01 愛爾康研究有限公司 穩定的藥學次微米懸浮液及其形成方法
CA2740746A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds comprising a spiro-ring and and methods of use
WO2010056758A1 (en) 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
CN101747306B (zh) 2008-11-28 2012-08-29 中国中化股份有限公司 取代醚类化合物及其应用
JP5471063B2 (ja) 2009-02-23 2014-04-16 住友化学株式会社 環状化合物、その金属錯体及び変性金属錯体
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
US20120022057A1 (en) 2009-03-18 2012-01-26 Schering Corporation Bicyclic compounds as inhibitors of diacyglycerol acyltransferase
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US9241928B2 (en) 2009-06-26 2016-01-26 The General Hospital Corporation Antimicrobial compounds
WO2011054433A1 (en) 2009-11-07 2011-05-12 Merck Patent Gmbh Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
EP2335686A1 (en) 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
DE102010006121B4 (de) 2010-01-29 2022-08-11 Merck Patent Gmbh Materialien für organische Elektrolumineszenzvorrichtungen
DE102010007938A1 (de) 2010-02-12 2011-10-06 Merck Patent Gmbh Elektrolumineszierende Polymere, Verfahren zu ihrer Herstellung sowie ihre Verwendung
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
JP5654246B2 (ja) 2010-03-03 2015-01-14 一般社団法人ファルマバレープロジェクト支援機構 キナゾリン化合物を有効成分とする医薬組成物
TWI516264B (zh) 2010-05-06 2016-01-11 臺北醫學大學 芳香醯喹啉化合物
JP5921535B2 (ja) 2010-06-16 2016-05-24 ディナバックス テクノロジーズ コーポレイション Ｔｌｒ７および／またはｔｌｒ９阻害剤を用いる治療の方法
DE102010023949A1 (de) 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
CA2803890A1 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
US20120252756A1 (en) 2010-06-25 2012-10-04 Coffey Martin J Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye
CN102958930B (zh) 2010-06-28 2018-04-27 默克专利有限公司 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
US20130190278A1 (en) 2010-07-29 2013-07-25 Laboratoires Fournier Sa Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases
KR20130042590A (ko) 2010-07-30 2013-04-26 랜박시 래보러터리스 리미티드 기질 메탈로프로테나제 저해제
TW201211007A (en) 2010-08-27 2012-03-16 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012040499A2 (en) 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
AU2011306397A1 (en) 2010-09-24 2013-05-02 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
CN103228634A (zh) 2010-09-24 2013-07-31 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
EP2619179A1 (en) 2010-09-24 2013-07-31 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
US9597325B2 (en) 2010-10-13 2017-03-21 Trustees Of Boston University Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
EP2629760A4 (en) 2010-10-22 2014-04-02 Bind Therapeutics Inc THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT
CA2816977C (en) 2010-11-05 2019-10-29 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
DE102010050570A1 (de) 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
WO2012064898A1 (en) 2010-11-09 2012-05-18 Yuan Chen Singleton inhibitors of sumoylation enzymes and methods for their use
WO2012071042A1 (en) 2010-11-24 2012-05-31 Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services Compositions and methods for treating or preventing lupus
WO2012074980A2 (en) 2010-12-01 2012-06-07 Dara Biosciences, Inc. Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012088431A1 (en) 2010-12-23 2012-06-28 Ironwood Pharmaceuticals, Inc. Faah inhibitors
US20140024627A1 (en) 2011-01-03 2014-01-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
US8980909B2 (en) 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
CA2826773C (en) 2011-02-24 2019-07-16 Emory University Jab1 blocking compositions for ossification and methods related thereto
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
WO2012135416A1 (en) 2011-03-29 2012-10-04 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors
US8507686B2 (en) 2011-04-14 2013-08-13 Allergan, Inc. Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
AU2012242807A1 (en) 2011-04-14 2013-11-07 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
AU2012245683A1 (en) 2011-04-18 2013-11-07 Allergan, Inc. Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
JP6211513B2 (ja) 2011-04-26 2017-10-11 ジェネンテック， インコーポレイテッド 自己免疫疾患の治療のための組成物及び方法
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis
TWI717552B (zh) 2011-05-12 2021-02-01 美商遠景生物製藥股份有限公司 具有類固醇類或非類固醇抗發炎藥之安定的普維酮－碘（Povidone-Iodine）組合物
WO2012158435A1 (en) 2011-05-17 2012-11-22 Han-Jie Zhou Compositions and methods for jamm protein inhibition
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
EA201490177A1 (ru) 2011-06-29 2014-08-29 Оцука Фармасьютикал Ко., Лтд. Хиназолины как терапевтические соединения и связанные с ними способы их применения
WO2013013614A1 (zh) 2011-07-28 2013-01-31 南京英派药业有限公司 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
JP5753027B2 (ja) 2011-08-22 2015-07-22 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子、化合物、並びに該素子を用いた発光装置、表示装置及び照明装置
TW201808311A (zh) 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物
WO2013061269A1 (en) 2011-10-26 2013-05-02 Micro Labs Limited Combinations of loteprednol and olopatadine for the treatment of ocular allergies
CA2850955C (en) 2011-11-03 2019-11-19 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
WO2013065028A1 (en) 2011-11-04 2013-05-10 Micro Labs Limited Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
US20130116279A1 (en) 2011-11-07 2013-05-09 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4
WO2013070852A2 (en) 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
CN103102342B (zh) 2011-11-14 2014-10-29 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
TWI577671B (zh) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN103102345B (zh) 2011-11-14 2015-06-03 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
WO2013074386A2 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
RU2631599C2 (ru) 2011-12-14 2017-09-25 Дзе Джонс Хопкинс Юниверсити Наночастицы, легче проникающие в слизистую оболочку или вызывающие меньше воспаления
CN103183674B (zh) 2011-12-31 2017-09-12 江苏先声药业有限公司 一类稠杂环衍生物及其应用
US9006257B2 (en) 2012-02-09 2015-04-14 Glenmark Pharmaceuticals S.A. Bicyclic compounds as mPGES-1 inhibitors
WO2013120057A1 (en) 2012-02-10 2013-08-15 The Regents Of The University Of California First row metal-based catalysts for hydosilylation
CN103304572A (zh) 2012-03-09 2013-09-18 上海医药集团股份有限公司 一类3-氰基喹啉类化合物及其药用组合物和应用
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
HK1208162A1 (en) 2012-05-03 2016-02-26 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
CN111700880A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
WO2013179144A2 (en) 2012-06-01 2013-12-05 Oxalys Pharmaceuticals Chemical suppressors of neurotoxicity in synucleinopathic diseases
CN104583206A (zh) 2012-06-15 2015-04-29 加利福尼亚大学董事会 用于脑癌的新颖治疗剂
US9062026B2 (en) 2012-07-20 2015-06-23 Cleave Biosciences, Inc. Fused pyrimidines and substituted quinazolines as inhibitors of p97
CN103804292A (zh) 2012-11-05 2014-05-21 江苏唐果医药科技有限公司 Hdm2和hdmx双重抑制剂3－腈基喹啉衍生物及其制备方法与应用
CA2890664A1 (en) 2012-11-08 2014-05-15 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions and their use as pkm2 modulators
US20150259649A1 (en) 2012-11-08 2015-09-17 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
US9701638B2 (en) 2012-11-09 2017-07-11 Rutgers, The State University Of New Jersey Therapeutic hydroxyquinolones
KR102051910B1 (ko) 2012-11-30 2019-12-09 에스에프씨주식회사 중수소 치환된 유기금속 착물 및 이를 포함하는 유기 발광 소자
CN103848785B (zh) 2012-12-04 2016-07-13 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
KR102146232B1 (ko) 2012-12-21 2020-08-20 메르크 파텐트 게엠베하 금속 착물
KR102084421B1 (ko) 2013-02-15 2020-03-05 에스에프씨주식회사 신규한 유기 화합물 및 이를 포함하는 유기 발광 소자
CN107915751A (zh) 2013-02-20 2018-04-17 卡拉制药公司 治疗性化合物和其用途
KR102118013B1 (ko) 2013-02-22 2020-06-05 에스에프씨주식회사 신규한 유기 화합물 및 이를 포함하는 유기 발광 소자
KR20150123908A (ko) 2013-03-04 2015-11-04 어드밴스드 메디컬 리서치 인스티튜트 오브 캐나다 퀴놀린 술포닐 유도체 및 그의 용도
WO2014141057A2 (en) 2013-03-12 2014-09-18 Mahesh Kandula Compositions and methods for the treatment of cancer
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
WO2014159837A1 (en) 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
CA2902734A1 (en) 2013-03-18 2014-09-25 Genoscience Pharma Quinolines derivatives as novel anticancer agents
WO2014182954A1 (en) 2013-05-08 2014-11-13 Colorado Seminary, Which Owns And Operates The University Of Denver Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
BR112015028760A2 (pt) 2013-05-16 2017-07-25 Us Health compostos para inibição de cepas de integrase do hiv-1 resistentes a drogas
JP6419802B2 (ja) 2013-10-14 2018-11-07 メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ 電子素子のための材料
WO2015066482A1 (en) * 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Also Published As

Publication number Publication date
JP2019038825A (ja) 2019-03-14
US20210355133A1 (en) 2021-11-18
CN106061261B (zh) 2018-04-24
MX2016005668A (es) 2016-10-28
US10160765B2 (en) 2018-12-25
US20160115176A1 (en) 2016-04-28
EP3062618B1 (en) 2020-02-05
CN108530458A (zh) 2018-09-14
KR20160099084A (ko) 2016-08-19
US20150125535A1 (en) 2015-05-07
CN106061261A (zh) 2016-10-26
AU2014342042A1 (en) 2016-05-12
US10975090B2 (en) 2021-04-13
WO2015066482A1 (en) 2015-05-07
US10618906B2 (en) 2020-04-14
JP6426194B2 (ja) 2018-11-21
AU2014342042B2 (en) 2017-08-17
EP3062618A1 (en) 2016-09-07
US11713323B2 (en) 2023-08-01
US20200216459A1 (en) 2020-07-09
MX355330B (es) 2018-04-16
EP3062618A4 (en) 2017-07-12
CA2928658A1 (en) 2015-05-07
JP2016535100A (ja) 2016-11-10
US9790232B2 (en) 2017-10-17
US20180009824A1 (en) 2018-01-11
US20190077810A1 (en) 2019-03-14
US9458169B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MX360598B (es) Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos.
TN2016000238A1 (en) Tricyclic compounds as anticancer agents.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
IN2015DN01156A (enExample)
MX2016002368A (es) Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1).
NZ700928A (en) Dna-pk inhibitors
MX2015009037A (es) Enjuague nasal con miel.
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX367897B (es) Derivados de piridazinona macrociclicos.
CA2818187C (en) Bromodomain inhibitors and uses thereof
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
MX370017B (es) Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
HK1217092A1 (zh) 治疗性化合物及其用途
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
IN2012DN00239A (enExample)
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
HK1228278A1 (en) Crystalline forms of therapeutic compounds and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2019 BY DENNEMEYER + CO

Effective date: 20180927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2020 BY DENNEMEYER + CO.

Effective date: 20190923

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2021 BY DENNEMEYER + CO.

Effective date: 20201019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2022 BY DENNEMEYER + CO.

Effective date: 20211018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2023 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20221024

LAPS Patent lapsed